The management of hypertension in Canada: a review of current guidelines, their shortcomings and implications for the future

McAlister, Finlay A.; Campbell, Norman R.C.; Zarnke, Kelly; Levine, Mitchell; Graham, Ian D.
February 2001
CMAJ: Canadian Medical Association Journal;2/20/2001, Vol. 164 Issue 4, p517
Academic Journal
Clinicians are exposed to numerous hypertension guidelines. However, their enthusiasm for these guidelines, and the impact of the guidelines, appears modest at best. Barriers to the successful implementation of a guideline can be identified at the level of the clinician, the patient or the practice setting; however, the shortcomings of the guidelines themselves have received little attention. In this paper, we review the hypertension guidelines that are most commonly encountered by Canadian clinicians: the "1999 Canadian Recommendations for the Management of Hypertension," "The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure" in the United States and the "1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension." The key points of these guidelines are compared and the shortcomings that may impede their ability to influence practice are discussed. The main implications for future guideline developers are outlined.


Related Articles

  • FDA EXTENDS TIMELINE FOR COMPLETION OF REMODULIN PHASE IV.  // Biotech Business;Oct2003, Vol. 16 Issue 10, p5 

    Reports that United Therapeutics Corp. has announced that the U.S. Food and Drug Administration has issued timelines for completion of a required Phase IV postmarketing study to further assess the clinical benefits of Remodulin, United Therapeutics' approved therapy for pulmonary arterial...

  • A wake-up call--and new guidelines--for hypertension. Pinkowish, Mary Desmond // Patient Care;1/15/1998, Vol. 32 Issue 1, p17 

    Reports on the failing efforts of clinicians in combating hypertension. Reference to the increase of stroke deaths and coronary heart disease; Differentiation of the report given by the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI)...

  • Severe paediatric pulmonary hypertension: new management strategies. Rashid, A.; Ivy, D. // Archives of Disease in Childhood;Jan2005, Vol. 90 Issue 1, p92 

    Pulmonary hypertension is a significant complication in many paediatric disease states. This article discusses current understanding of pulmonary hypertension and includes definition, diagnosis, and management. A description of the latest advances in targeted pharmacological therapy in children...

  • Controversies in Blood Pressure Management in Hemodialysis. CHANG, TARA I. // Renal & Urology News;Apr2014, Vol. 13 Issue 4, p12 

    The article discusses the controversies in blood pressure (BP) management in patients on hemodialysis (HD). It explains the uncertain best method of BP management fo HD patients with hypertension and cardiovascular disease. It explores several studies that correlate measurements poorly with...

  • Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. Gibbs, J. Simon R. // Heart;Mar2008 Supplement 1, Vol. 94, pi1 

    The article provides information on the consensus statement concerning the major advancement in pulmonary hypertension (PH) management in clinical practice in Great Britain and Ireland. It has been noted that the purpose of the consensus statement is to update the 2001 recommendations to...

  • Ciclosporin.  // Reactions Weekly;9/8/2007, Issue 1168, p11 

    The article presents a case study of a four-year old boy who developed leukoencephalopathy during treatment with ciclosporin for focal segmental glomerulosclerosis presenting as corticosteroid-resistant nephrotic syndrome. He was hospitalized and started receiving ciclosporin and afterwards,...

  • Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies. Fen Wei; Xiu-Jie Jia; Su-Qin Yu; Ye Gu; Li Wang; Xiao-Mei Guo; Min Wang; Feng Zhu; Xiang Cheng; Yu-Miao Wei; Zi-Hua Zhou; Micheal Fu; Yu-Hua Liao // Heart;Mar2011, Vol. 97 Issue 6, p479 

    Background Anti-angiotensin II receptor subtype 1 (AT1 receptor) autoantibodies have previously been shown in sera of hypertensive patients. This study assessed whether anti-AT1-receptor autoantibody in serum is correlated with the efficacy of an AT1-receptor blocker (ARB; candesartan)-based...

  • Pulmonary Hypertension. Gaine, Sean // JAMA: Journal of the American Medical Association;12/27/2000, Vol. 284 Issue 24, p3160 

    Presents the case of a 44-year-old businesswoman with primary pulmonary hypertension (PPH). Background on symposiums held on PPH by the World Health Organization; Classification of pulmonary hypertension; Diagnostic evaluation; General approach to treatment; Pathophysiological characteristics...

  • THE PERIPHERAL PULSE AS A DIAGNOSTIC TOOL. McLean, Charles E.; Clason, W. Page C.; Stoughton, Peter V. // Angiology;May1964, Vol. 15 Issue 5, p221 

    One hundred six normal people were studied for variations of eight pulse pressure parameters dealing with time and pressure measurements as obtained through a left brachial artery needle. Two hundred twenty-two patients including nine separate disease states were studied in the same fashion. An...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics